You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH)半年度淨利潤升9.47%至6.38億元
格隆匯 08-21 16:40

格隆匯8月21日丨華潤雙鶴(600062.SH)發佈2019年半年度報告,實現營業收入48.66億元,同比增長19.03%;歸屬於上市公司股東的淨利潤6.38億元,同比增長9.47%;歸屬於上市公司股東的扣除非經常性損益的淨利潤6億元,同比增長7.14%;基本每股收益0.612元。

2019年上半年公司實現主營業務收入47.64億元,同比增長17.45%。

慢病業務收入同比增長16%,其中降壓領域增長9%,降糖領域增長15%,降脂領域增42%。降壓領域壓氏達、穗悦、復穗悦和硝苯地平緩釋片均呈現雙位數增長降糖藥重點產品糖適平(格列喹酮片)銷售收入同比增長4%,卜可(鹽酸二甲雙胍緩釋片)上半年已通過一致性評價,銷售收入實現66%的快速增長;降脂藥匹伐他汀鈣片繼續保持高速增長,銷售收入同比增長42%,為公司第三大慢病產品;腦血管用藥胞磷膽鹼鈉片銷售收入亦實現雙位數增長。

專科業務收入同比增長87%,其中兒科用藥領域增幅達到16%,核心產品珂立蘇銷售收入同比增長11%;腎科用藥領域同比增長29%,核心產品腹膜透析液保持高速增長,銷售收入同比增長26%;新佈局的精神神經領域貢獻收入2.26億元。

輸液業務收入同比增長4%;基礎輸液今年銷量保持穩定,包材結構調整再突破,軟包裝銷量增長6%,軟包裝銷量佔比較2018年再提升2個百分點,其中BFS收入同比增長66%直軟輸液收入同比增長20%

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account